BCL-2 rearranged B cell clones in chronic HCV infection: a possibile factor negatively influencing the virological response to treatment

Hepatitis C virus (HCV) has been recognized as a major cause of chronic liver diseases worldwide. It has been suggested that HCV infects not only hepatocytes but also mononuclear lymphocytes including B cells that express the CD81 molecule, a putative HCV receptor. HCV infection of B cells is the likely cause of B-cell dysregulation disorders such as mixed cryoglobulinemia, rheumatoid factor production, and B-cell lymphoproliferative disorders that may evolve into non-Hodgkin's lymphoma (NHL). Epidemiological data indicate an association between HCV chronic infection and the occurrence of B-cell NHL, suggesting that chronic HCV infection is associated at least in part with B-cell lymphomagenesis. In this paper, we aim to provide an overview of recent literature, including our own, to elucidate a possible role of HCV chronic infection in B-cell lymphomagenesis.

Download Full-text

CD4+CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses

Journal of Hepatology ◽

10.1016/j.jhep.2014.09.024 ◽

2015 ◽

Vol 62 (2) ◽

pp. 303-310 ◽

Cited By ~ 34

Author(s):

Michelle Spaan ◽

Kim Kreefft ◽

Gretchen N. de Graav ◽

Willem P. Brouwer ◽

Robert J. de Knegt ◽

...

Keyword(s):

T Cells ◽

B Cell ◽

Hcv Infection ◽

Cell Responses ◽

Chronic Hcv Infection ◽

B Cell Responses ◽

Chronic Hcv

Download Full-text

Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection

Journal of Viral Hepatitis ◽

10.1111/j.1365-2893.2010.01288.x ◽

2011 ◽

Vol 18 (2) ◽

pp. 129-134 ◽

Cited By ~ 7

Author(s):

P. Rosenberg ◽

K. Hagen

Keyword(s):

Hcv Infection ◽

Response To Treatment ◽

Chronic Hcv Infection ◽

Chronic Hcv

Download Full-text

Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome

Journal of Investigative Medicine ◽

10.1136/jim-2016-000343 ◽

2017 ◽

Vol 65 (4) ◽

pp. 765-771 ◽

Cited By ~ 7

Author(s):

Prashant Pandya ◽

Chaitanya Pant ◽

Ryan Taylor ◽

Olurinde Oni

Keyword(s):

Diabetes Mellitus ◽

Metabolic Syndrome ◽

Sustained Virological Response ◽

Virological Response ◽

Hcv Infection ◽

History Of ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

New Onset

The high cost associated with antiviral treatment for chronic hepatitis C virus (HCV) infection mandates further investigation in the context of preventing complications such as type 2 diabetes mellitus (DM2). We determined the cumulative incidence of DM2 in subjects with chronic HCV infection who received concomitant pegylated interferon (Peg-IFN) and ribavirin. We conducted a retrospective analysis of data obtained from Veterans Administrations Informatics and Computing Infrastructure (VINCI) to identify an adult cohort of patients without diabetes with chronic HCV infection who received Peg-IFN-based therapy between October 2001 and December 2011. Patients with history of HIV, hepatitis B infection, hepatocellular cancer (HCC), non-HCC cancers, and history of transplantation were excluded. Sustained virological response (SVR) was defined as negative HCV RNA 3 months after completion of therapy. Using Cox proportional hazards regression for multivariable analysis, we determined that patients who achieved SVR were at a significantly less risk of developing DM2. Adjusted survival rates showed that the responders' group was significantly less likely to develop DM2 over time (HR 0.60, CI 0.48 to 0.74, p<0.001). Peg-IFN-based therapy in chronic HCV patients that resulted in SVR significantly decreased the risk of developing DM2 and independently predicts the development of new onset disease after controlling for correlates of metabolic syndrome.

Download Full-text